Wells Fargo & Company Intellia Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding NTLA
# of Institutions
326Shares Held
88.8MCall Options Held
673KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.6MShares$229 Million2.36% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$189 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.1MShares$179 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$94.7 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$86 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.5B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...